CHRIS DAVIS,DAMIEN FRAYSSE,DAVID KAY,DAVID SHAW,DEAN BOYALL,DONALD MIDDLETON,FRANCOISE PIERARD,GORKA ETXEBARRIA I JARDI,HEATHER TWIN,JEAN-DAMIEN CHARRIER,JOANNE PINDER,JOHN STUDLEY,JUAN-MIGUEL JIMENEZ
申请号：
BR112015012454
公开号：
BR112015012454A8
申请日:
2013.12.06
申请国别(地区):
BR
年份:
2019
代理人:
摘要：
abstract [0001] the present invention relates to compounds useful as inhibitors of atr protein kinase. the invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention； methods of treating of various diseases, disorders, and conditions using the compounds of this invention； processes for preparing the compounds of this invention； intermediates for the preparation of the compounds of this invention； and methods of using the compounds in vitro applications, such as the study of kinases in biological and pathological phenomena； the study of intracellular signal transduction pathways mediated by such kinases； and the comparative evaluation of new kinase inhibitors. [0002] the compounds of this invention have formula i: or a pharmaceutically acceptable salt, wherein the variables are as devined herein. [0003] moreover, the compounds of this invention have formula i: a: a pharmaceutically acceptable salt, wherein the variables are defined herein. translation of the abstract summary: patent for "compounds useful as atrinase inhibitors". The present invention relates to compounds useful as inhibitors of atr protein kinase. The invention likewise relates to pharmaceutically acceptable compositions comprising the compounds of this invention； methods of treating various diseases, disorders, and conditions using the compounds of this invention； processes for preparing the compounds of this invention； intermediates for the preparation of the compounds of this invention； and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena； the study of intracellular signal transduction reaction series mediated by such kinases； and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula (I) or a pharmaceutically acceptable salt, wherein the variables are as defined herein. In addition, the compounds of this invention have formula
